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Benign prostatic hyperplasia and associated lower urinary tract symptoms (BPH/LUTS) are
common conditions affecting the majority of elderly males. Here we report the results of a
genome-wide association study of symptomatic BPH/LUTS in 20,621 patients and 280,541
controls of European ancestry, from Iceland and the UK. We discovered 23 genome-wide
signiﬁcant variants, located at 14 loci. There is little or no overlap between the BPH/LUTS
variants and published prostate cancer risk variants. However, 15 of the variants reported
here also associate with serum levels of prostate speciﬁc antigen (PSA) (at a Bonferroni
corrected P < 0.0022). Furthermore, there is a strong genetic correlation, rg= 0.77 (P=
2.6 × 10−11), between PSA and BPH/LUTS, and one standard deviation increase in a polygenic
risk score (PRS) for BPH/LUTS increases PSA levels by 12.9% (P= 1.6×10−55). These results
shed a light on the genetic background of BPH/LUTS and its substantial inﬂuence on PSA
levels.
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Benign prostatic hyperplasia (BPH), the nonmalignantenlargement of the prostate, and associated lower urinarytract symptoms (LUTS) are common medical conditions
among elderly males. Autopsy studies have unveiled a histological
prevalence of the disease of: 8, 50, and 80%, in the fourth, sixth,
and ninth decades of life, respectively1. BPH contributes to
bladder outlet obstruction, leading not only to bothersome LUTS
but can, if untreated, be detrimental to patients’ health by
affecting bladder and kidney function. Furthermore, BPH/LUTS
is associated with depression, and diminished health-related
quality of life; based on sleep, psychological condition, activities
in daily life, and sexual activities2–4. The high prevalence of BPH/
LUTS and its effect on various other health related conditions
results in a high annual health-care cost, both for patients and
societies. This cost is likely to rise dramatically over the next few
decades as life expectancy is on the rise in most countries. The
detailed molecular pathogenesis of BPH/LUTS has not been well
established. However, in addition to age, inﬂammation5, sex
hormones6, and metabolic factors7 have all been implicated.
Furthermore, genetic variation is a strong risk factor for devel-
oping BPH/LUTS. A study of men who underwent surgery for
BPH younger than 64 years of age, reported that other male
relatives and brothers of probands had a four- and six fold
increase, respectively, of age-speciﬁc risks of BPH surgery8. In
addition, twin studies report the concordance rate ratios for BPH/
LUTS to range between 2.2 and 6.9 depending on the speciﬁcity
of symptom deﬁnition9, 10. Despite this relatively strong genetic
component of the disease, only very few suggestively associated
sequence variants have been reported for BPH/LUTS11–14.
In order to search for variants conferring risk of symptomatic
BPH/LUTS, we performed a genome-wide association study
(GWAS) in two study groups, coming from Iceland and the UK
Biobank15. We report here genome-wide signiﬁcant results for 23
genetic variants, located at 14 loci, conferring risk of symptomatic
BPH/LUTS.
Results
GWAS analysis. The GWAS of the Icelandic BPH/LUTS dataset
included 9443 men with symptomatic BPH/LUTS and 104,000
controls. Men with symptomatic BPH/LUTS were deﬁned as
individuals undergoing transurethral resection of the prostate
(TURP), as well as men older than 50 years, repeatedly using
drugs for treating BPH/LUTS belonging to the G04C group of the
Anatomical Therapeutic Chemical (ATC) classiﬁcation (for
example: tamsulosin, ﬁnasteride, and dutasteride).
The UK Biobank dataset consists of 11,178 men with BPH/
LUTS according to hospital-based diagnosis, as well as 176,541
controls not known to have been diagnosed with BPH/LUTS. For
a description of the genotyping and imputation of the Icelandic
and UK Biobank samples (see the Methods section).
Per-allele odds ratios (ORs) and two-sided P-values for all
~42.9 million variants in the GWASs of both study groups were
obtained using a logistic regression model. We then conducted a
ﬁxed-effect meta-analysis including the Icelandic and the UK
results with 20,621 patients and 280,541 controls, in total.
Association with BPH/LUTS. An initial screening of the GWAS
results revealed 14 variants, at 14 loci, surpassing our genome-
wide signiﬁcance criteria (Table 1, Supplementary Tables 1 and 2,
Fig. 1, Supplementary Fig. 1 and 2). The threshold for genome-
wide signiﬁcance in the present study was corrected for multiple
testing using a weighted Bonferroni procedure based on func-
tional impact of classes of variants16 (for our GWAS the sig-
niﬁcance thresholds range between 1.9 × 10−7 and 5.9 × 10−10
depending on functional annotations; see Methods). For all 14
variants the effect estimates in the Icelandic and UK samples were
highly consistent and no signiﬁcant heterogeneity was detected
when considering the number of variants tested (a Bonferroni
corrected P-value of 0.05/14= 0.0036).
In order to search for additional association signals, we
performed a stepwise CGTA-COJO17 conditional analysis at the
14 newly discovered risk loci. We found 9 secondary association
signals at 8 loci after conditioning on the lead marker at each of
the 14 loci. For the variants identiﬁed with the COJO method, we
then performed a conditional analysis using individual genotypes
(Table 1, Supplementary Table 2, and Methods). The signiﬁcance
threshold for the combined results from the conditional analyses
was set at P < 1 × 10−6 since, when performing the conditional
analyses we tested approx. 50,000 markers (Bonferroni correc-
tion: 0.05/50,000= 1.0 × 10−6). For information about pairwise
linkage disequilibrium (LD) between lead variants at loci with
multiple association signals, see Supplementary Table 3. In total,
the unconditional GWAS and conditional analysis returned 23
variants, associated with symptomatic BPH/LUTS in our study.
Thereof, 3 are rare or low frequency (with an average minor allele
frequency (MAF) ≤ 8%) and 2 of those are missense variants
(Table 1). All variants reported in Table 1 had imputation
information score > 0.95, except rs200383755, which had an
imputation information score of 0.99 and 0.88 in the Icelandic
and UK datasets, respectively.
Bioinformatics and quantitative trait locus analyses of risk
variants. Our bioinformatics and expression quantitative trait
locus analyses yielded several interesting ﬁndings for the newly
discovered BPH/LUTS variants. Especially noticeable was the
high fraction of risk loci (14 out of 23) with variants identiﬁed
within regions marked by acetylation of histone H3 at lysine
residue K27 (H3K27ac) in prostate epithelial cells. The H3K27ac
mark is a well-known marker of active regulatory regions found
within enhancers and gene promoters. Below we summarize
ﬁndings for 3 of the 14 BPH/LUTS risk loci, for a more detailed
information about all 23 variants located at the 14 BPH/LUTS
risk loci, see Supplementary Note 1, Supplementary Table 4, and
Supplementary Data 1 and 2.
The 12q24.21 locus has two independently associated BPH/
LUTS variants. rs2555019 is located intergenic and downstream
of TBX5, a member of a gene family that encodes transcription
factors involved in regulation of embryonic developmental
processes. The other variant, rs8853, is correlated (r2= 0.64)
with rs11067228 reported to associate with serum levels of
prostate-speciﬁc antigen (PSA)18 and it is located in the 3′-
untranslated region (UTR) of TBX3, belonging to the same gene
family as TBX5. Germline mutations in TBX3 underlie ulnar
mammary syndrome, a rare pleiotropic developmental disorder
characterized by altered: upper limbs, apocrine and mammary
glands, and genitals19. According to the Genotype-Tissue
Expression (GTEx) analysis, based on multiple tissues, the
expression of TBX3 is reported to rank second and third highest
in bladder and prostate tissues, respectively. Based on our focused
analysis of promoters/enhancer regions in prostate epithelial cells
we found the 12q24.12 locus (with rs8853 as a lead variant) to
intersect with a super-enhancer and to have a clear tissue-
speciﬁcity with respect to the H3K27ac mark in prostate-derived
cells (Fig. 2a). Furthermore, based on a recently developed
enhancer-gene target resource, referred to as the Joint Effect of
Multiple Enhancers (JEME), TBX3 is the only candidate target
gene, in primary prostate tissue samples, linked to this enhancer
element.
rs1638703 and rs6561599 on 13q14.3 are independently
associated with BPH/LUTS according to our results. rs1638703
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is fully correlated (r2= 1) with rs202346, which has been reported
to associate with serum levels of PSA18 and it is located intronic
within the non-protein coding gene DLEU1, whereas rs6561599 is
located some 5 kb upstream of RNASEH2B. The protein encoded
by this gene is the non-catalytic B-subunit of RNase H2
endonuclease complex, which is thought to play a role in nucleic
acid metabolism to preserve genome stability and to prevent
immune activation20. Our focused analysis (with rs6561599 as a
lead variant) of promoters/enhancers revealed a tissue-speciﬁc
promoter region for RNASEH2B, wherein the H3K27ac mark was
particularly prevalent in prostate-derived cells (Fig. 2b).
The 20q13.33 locus also contains two variants independently
associated with BPH/LUTS. One of these variants, rs200383755_C,
is a missense variant (p.Ser19Trp) in the GATA5 gene. In our
combined study group this variant has a minor allelic frequency of
0.9%, and confers strong protection against BPH/LUTS, with an
OR= 0.67 and P= 3.2 × 10−9 (Table 1). Correspondingly, Icelan-
dic carriers of this variant underwent a TURP treatment 2.7 years
older (P= 0.013) than non-carriers (see Supplementary Table 5).
The GATA5 gene encodes a transcription factor that contains two
GATA-type zinc ﬁngers and is required during cardiovascular
development21. According to the GTEx Portal, GATA5 has the
highest expression in bladder but its expression is also relatively
high in prostate tissue, ranking seventh from the top. The other
independently associated variant at 20q13.33 is rs6061244_C
(OR= 0.94 and P= 5.7 × 10−8; Table 1), located intronic in
GATA5, and as it has no strongly correlated variants (r2 > 0.75) it
can be considered a probable causative variant.
Prostate cancer and BPH/LUTS can coexist in elderly men, e.g.
in the Icelandic BPH/LUTS study group 15% of the men have
also been diagnosed with prostate cancer and 8.8% in the UK
sample set. Two of the BPH/LUTS variants discovered in our
study have previously been reported to associate with risk of
prostate cancer, i.e. rs2555019 (it has r2= 0.81 with rs127088422)
located downstream of TBX5 on 12q24.21, and rs11651052
(which has r2= 0.91 with rs443079623) located intronic in
HNF1B on 17q12. Therefore, we performed a GWAS of BPH/
LUTS, where we excluded all men known to have prostate cancer,
included in our study groups (see Supplementary Table 6). The
results from this analysis did not yield any new genome-wide
signiﬁcant BPH/LUTS loci but the results for rs11651052 on
chromosome 17q12 fell well below our threshold of genome-wide
signiﬁcance. The combined unconditional association results for
rs11651052_A and the total list of BPH/LUTS (i.e. including men
also with prostate cancer) were: OR= 0.93 and P= 3.2 × 10−10,
whereas the unconditional results for men only known to have
BPH/LUTS were: OR= 0.95 and P= 7.5 × 10−6 (see Supplemen-
tary Tables 2 and 6). It is therefore possible that our initial BPH/
LUTS association signal for rs11651052 was inﬂated due to a
confounding effect from men diagnosed with both BPH/LUTS
and prostate cancer (i.e. the association effects for BPH/LUTS
and prostate cancer are in the same direction, see Supplementary
Table 7). The observed difference could also be due to a chance
based on who were and who were not removed from the study
group for the purpose of this focused analysis. However,
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Fig. 1 A Manhattan plot of the combined BPH/LUTS GWAS results. The Manhattan plot shows variants with two-sided P-value < 0.10 (obtained using a
logistic regression model) and high imputation information score (info > 0.90) from the BPH/LUTS meta-analysis of GWAS data from 20,621 patients and
280,541 controls of European ancestry, coming from Iceland and the UK. Shown are negative log10-transformed two-sided P-values from the unconditional
analysis (y-axis) over 22 autosomes (x-axis). Dots colored in red denote variants that surpass our genome-wide signiﬁcance thresholds (ranging between
1.9 × 10−7 and 5.9 × 10−10), deﬁned using a weighted Bonferroni procedure based on functional impact of classes of variants
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effect is likely to be challenging and probably requires a very large
sample set, preferably including several populations.
The BPH/LUTS association results for the variant on 12q24.21
(rs2555019_T) became more signiﬁcant after excluding men
diagnosed with both BPH/LUTS and prostate cancer. The
unconditioned combined association results for rs2555019_T
and the total list of BPH/LUTS (i.e. including men also with
prostate cancer) were: OR= 0.93 and P= 1.4 × 10−10, whereas
the unconditioned combined results for men only known to have
BPH/LUTS were: OR= 0.92 and P= 3.0 × 10−12 (see Supple-
mentary Tables 2 and 6). This is probably because the effect
estimates for BPH/LUTS and prostate cancer are in the opposite
direction (see Supplementary Table 7). However, for clarity and
consistency of the data, the results reported in Table 1 for
rs2555019 are based on the total list of men with BPH/LUTS (i.e.
including men with prostate cancer), same as for the rest of the
data in Table 1.
Genetic correlation between serum levels of PSA and BPH/
LUTS. Nine of the BPH/LUTS variants discovered in our study
have previously been reported18, 24 to be genome-wide sig-
niﬁcantly associated with serum levels of PSA (Supplementary
Tables 7 and 8). These results and the fact that BPH is known25 to
increase serum PSA levels, prompted us to check the association
of all 23 BPH/LUTS variants with serum levels of PSA in a sample
set of 33,572 Icelandic males, not known to have been diagnosed
with prostate cancer or symptomatic BPH/LUTS. Our analysis
showed that in total, 15 of the 23 BPH/LUTS variants reported
here also associate with PSA levels at a Bonferroni corrected
signiﬁcance threshold (P < 0.0022; see Supplementary Table 7).
Moreover, the effect estimates for BPH/LUTS and PSA levels are
directionally consistent for all 15 variants (see Supplementary
Fig. 3).
We estimated the genetic correlation between serum levels of
PSA and BPH/LUTS, using cross-trait LD score regression26 and
the summary statistics from our GWAS of PSA in Iceland and the
corresponding data from the GWAS of BPH/LUTS in the UK
samples. Our results show a very strong genetic correlation (rg=
0.77; P= 2.6 × 10−11, see Supplementary Table 9) between PSA
levels and BPH/LUTS, across these two study populations. For
comparison purposes, we checked the genetic correlation between
serum levels of PSA and prostate cancer across the same two
study populations. Our results demonstrate a strong genetic
correlation (rg= 0.41; P= 6.1 × 10−5) between serum levels of
PSA and prostate cancer but still it is much weaker than for BPH/
LUTS and PSA levels. For comparison, our results indicate that
the genetic correlation (rg) between BPH/LUTS and prostate
cancer is 0.17, although nonsigniﬁcant (P= 0.18, see Supple-
mentary Table 9).
Polygenic risk scores. We also calculated polygenic risk scores
(PRSs) to estimate the contribution of variants that associate with
BPH/LUTS or prostate cancer, respectively, to variation in PSA
levels. We used effect estimates from the GWAS of BPH/LUTS
and prostate cancer in the UK samples to generate PRSs to cor-
relate with serum levels of PSA in the 18,929 Icelandic men (see
Methods). The PRSs for BPH/LUTS and prostate cancer correlate
very signiﬁcantly with PSA levels; each standard deviation (SD)
increase in the PRSs corresponds to 12.9% (P= 6.0 × 10−45) and
16.3% (P= 9.8 × 10−68) increase in PSA levels, respectively
(Table 2a). The effects of the PRSs for BPH/LUTS and prostate
cancer on PSA levels are largely independent since, in a joint
analysis the effect of both remained highly signiﬁcant, i.e. 8.6%
Table 1 Results from the meta-analysis of Icelandic and UK GWAS of symptomatic BPH/LUTS and from the the conditional
analysis for loci with multiple variants
Locus Marker (EA/OA) Covariate Annotation/nearby gene(s) EAF Phet/I2(%) Meta-analysis results
OR (95% c.i.) P-value
2p16.1 rs2556378 (T/G) rs10180282 Intron variant/BCL11A 0.154 0.37/0 1.12 (1.08, 1.15) 3.4 × 10−12
2p16.1 rs10180282a (T/C) rs2556378 Intergenic variant/BCL11A 0.456 0.58/0 1.06 (1.03, 1.08) 8.7 × 10−7
5p15.33 rs381949 (A/G) rs2853677 Intron variant/CLPTM1L 0.415 0.86/0 0.90 (0.88, 0.92) 4.9 × 10−19
5p15.33 rs2853677a (G/A) rs381949 Intron variant/TERT 0.421 0.44/0 1.09 (1.06, 1.11) 1.7 × 10−12
5q22.1 rs10054105 (G/T) na Intergenic variant/STARD4 0.213 0.65/0 0.91 (0.88, 0.93) 3.5 × 10−12
5q31.1 rs677394 (G/C) na Intron variant/C5orf66, H2AFY 0.123 0.034/78 0.88 (0.85, 0.92) 2.9 × 10−11
6p22.1 rs200476 (T/A) na Intergenic variant/HIST1H2BL 0.162 0.23/30 0.88 (0.85, 0.90) 3.9 × 10−17
10p12.31 rs148678804 (A/G) rs7906649 Intergenic variant/DNAJC1 0.035 0.17/48 1.27 (1.19, 1.35) 3.0 × 10−14
10p12.31 rs7906649a (G/A) rs148678804 Intergenic variant/EBLN1 0.286 0.71/0 1.07 (1.04, 1.10) 2.1 × 10−7
10q26.12 rs11199879 (C/T) rs4548546 and rs2981575 Intergenic variant/FGFR2 0.252 0.021/81 1.14 (1.11, 1.17) 5.7 × 10−23
10q26.12 rs4548546a (T/C) rs11199879 and rs2981575 Intron variant/WDR11 0.310 0.20/40 1.11 (1.08, 1.13) 2.0 × 10−16
10q26.12 rs2981575a (G/A) rs11199879 and rs4548546 Intron variant/FGFR2 0.427 0.97/0 0.94 (0.92, 0.96) 6.0 × 10−8
11p15.5 rs72878024 (A/G) na Missense variant/ODF3 0.080 0.20/40 0.85 (0.82, 0.89) 1.4 × 10−12
12q24.21 rs2555019 (T/C) rs8853 Intergenic variant/TBX5 0.456 0.82/0 0.93 (0.91, 0.95) 2.4 × 10−11
12q24.21 rs8853a (C/T) rs2555019 3-prime UTR variant/TBX3 0.494 0.75/0 1.07 (1.05, 1.10) 1.4 × 10−9
13q14.3 rs1638703 (C/G) rs6561599 Intron variant/DLEU1 0.256 0.57/0 1.10 (1.07, 1.13) 1.1 × 10−13
13q14.3 rs6561599a (C/G) rs1638703 Upstream gene variant/RNASEH2B 0.371 1.0/0 0.94 (0.92, 0.96) 1.8 × 10−7
17q12 rs11651052 (A/G) na Intron variant/HNF1B 0.470 0.24/29 0.93 (0.91, 0.95) 3.2 × 10−10
18q11.2 rs9958656 (T/C) rs17670370 Intergenic variant/GATA6 0.430 1.0/0 1.11 (1.08, 1.13) 4.3 × 10−19
18q11.2 rs17670370a (G/T) rs9958656 Intergenic variant/CTAGE1 0.262 0.24/28 1.07 (1.04, 1.10) 1.6 × 10−7
19q12 rs11084596 (C/T) na Intergenic variant/THEG5 0.356 0.34/0 0.88 (0.86, 0.90) 2.1 × 10−24
20q13.33 rs200383755 (C/G) rs6061244 Missense variant/GATA5 0.0091 0.53/0 0.67 (0.59, 0.77) 3.2 × 10−9
20q13.33 rs6061244a (C/G) rs200383755 Intron variant/GATA5 0.386 0.16/49 0.94 (0.92, 0.96) 5.7 × 10−8
Shown is the effect allele (EA), the other allele (OA), the simple average effect allele population frequency (EAF), the allelic odds ratio (OR) for the effect allele with upper and lower 95% conﬁdence
intervals (c.i.) and the two-sided P-value for association testing between variants and disease, which was performed using the likelihood ratio statistic. Results from the two study groups were combined
using a Mantel-Haenszel model (see Methods). Annotation is according to Variant Effect Predictor (VEP). Shown are also the P-value for the heterogeneity (Phet) between the two study groups and the
heterogeneity statistic (I2) representing the fraction of variability due to heterogeneity between study groups. rs200383755 had an imputation information score of 0.99 and 0.88 in the Icelandic and UK
datasets, respectively. All other markers listed had imputation information score >0.95. Results for markers pertaining to loci with more than one association signal are shown after conditioning on a
relevant covariate. Markers at loci with no additional association signal do not have any applicable covariate (na) and the results are the unconditioned association result from the GWAS of symptomatic
BPH/LUTS
aMarkers discovered in the conditional analysis
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increase (P= 3.0 × 10−20) and 13.3% increase (P= 4.1 × 10−43),
respectively (Table 2b). This is consistent with the observation
that the PRS for BPH/LUTHS has little predictive power for
prostate cancer, and vice versa; one SD increase in the PRS for
BPH/LUTS increased the risk for prostate cancer by about 4% (P
= 0.059), and the same increase of the prostate cancer PRS results
in about 5% increase of BPH/LUTS risk (P= 0.0027; see Sup-
plementary Table 10). These results demonstrate that variants
conferring risk of BPH/LUTS and their effects on PSA levels
warrant being taken into consideration when interpreting mea-
surements of individual PSA levels, performed in order to screen
for prostate cancer.
Discussion
In summary, through a GWAS we have discovered the ﬁrst set of
BPH/LUTS risk variants that surpass a genome-wide signiﬁcance
threshold. The majority (15 out of 23) of the variants reported
here also associate with serum levels of PSA. We show that
genetic correlation between BPH/LUTS and PSA levels is of a
similar magnitude to the genetic correlation between prostate
cancer and PSA levels. This underlines the complexity of inter-
preting the commonly applied PSA test, intended to screen for
prostate cancer. Interestingly, the BPH/LUTS variants reported
here are largely independent of the previously reported prostate
cancer risk variants, highlighting the difference in the etiologies of
these two prostate diseases. The drugs currently prescribed for
patients with BPH/LUTS do not cure the disease but provide a
relief of the symptoms, though that relief does not come without
side effects. In order to improve treatment, a better understanding
of the basic disease-causing factors is needed. Our results provide
several potential focus points for future research within this ﬁeld.
Methods
Study populations. The Icelandic BPH/LUTS study population consists of 9443
men with symptomatic BPH/LUTS and 104,000 controls. Men with symptomatic
BPH/LUTS were deﬁned as individuals diagnosed after undergoing TURP between
1983 and 2017 (70% of the total list). Also, included are men older than 50 years
repeatedly using drugs in the G04C group of the ATC classiﬁcation (for example,
tamsulosin, ﬁnasteride, and dutasteride) for treating BPH/LUTS between the years
2003 and 2009 (30% of the total list). The BPH/LUTS patients had a mean age of
71 years based on age at ﬁrst TURP treatment or youngest age in prescribed drug
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Fig. 2 GWAS variants intersecting with regulatory regions deﬁned on the basis of acetylation of histone H3 at lysine residue K27 (H3K27ac). Shown are
results for two of the loci reported to associate with BPH/LUTS from an analysis of non-coding risk variants intersecting with regulatory regions deﬁned on
the basis of acetylation of histone H3 at lysine residue K27 (H3K27ac), indicative of regulatory regions, in primary prostate epithelial cells. The y-axis
shows the ChIP-seq signal for the H3K27ac mark represented as negative log10 of the P-value and the x-axis shows the genomic location (hg38). The black
tick marks (top of panels a and b) indicate the position of variants found in strong LD (r2 > 0.8) with the lead variant, deﬁning an LD class, wherein rs
numbers are shown for those residing within H3K27ac signiﬁcant regions. a At 12q24.21 four variants reside within an H3K27ac marked region (rs71807,
rs8853, rs484443, and rs551510). b At 13q14.3, only one variant, rs2274069, belonging to the LD class of the lead variant resides within a H3K27ac
marked region. This is the promoter region for RNASEH2B, located within 500 bp from the transcription start site of the gene
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Icelandic prostate cancer GWAS group consisted of 5897 men diagnosed with
prostate cancer (mean age at diagnosis is 71 years) according to a nationwide list
from the Icelandic Cancer Registry (ICR) and the controls were 102,276 males
absent from the same list. The Icelandic study group used for GWAS of serum
levels of PSA consists of 33,572 men who had their PSA level measured between
1994 and 2014, and are not known to have been diagnosed with BPH/LUTS or
prostate cancer according to relevant nationwide patient lists. This study was
approved by the Data Protection Commission of Iceland and the National
Bioethics Committee of Iceland (License No.: VSN-17-026 and VSN-18-029)
Written informed consent was obtained from all subjects requited for blood
samples. Personal identiﬁers associated with medical information and blood
samples were encrypted with a third-party encryption system.
The UK Biobank BPH/LUTS dataset (accessed under Application Number:
24711) consists of 11,178 men with symptomatic BPH/LUTS, according to
hospital-based diagnosis (ICD10 code=N40), as well as 176,541 male controls, not
known to have been diagnosed with BPH/LUTS. For the UK GWAS of prostate
cancer (ICD10 code= C61) we used 5811 men diagnosed with prostate cancer and
181,908 male controls not know to have prostate cancer.
Genotyping. The Icelandic BPH/LUTS-, prostate cancer-, and PSA-level GWAS
datasets used in the current study are based on whole-genome sequencing, chip
genotyping and imputation, aided by long-range phasing of Icelandic population
samples27. In brief, we whole-genome-sequenced 15,220 Icelanders using Illumina
technology (Illumina, San Diego, CA, USA) to an average depth of at least 34×,
resulting in the identiﬁcation of some 94 million variants. Using imputation
assisted by long-range haplotype phasing28, 29 and after removing variants with
imputation information content below 0.8 as well as with an imputed MAF below
0.01%, we successfully inferred the genotypes of 32,463,443 variants in 434,571
Icelanders, of whom 151,677 had been genotyped using the Illumina chip geno-
typing platform. The remaining 282,894 Icelanders are ﬁrst- and second-degree
relatives of the chip-typed individuals and are imputed by aid of genealogic
information.
Genotyping of UKB samples was performed using a custom-made Affymetrix
chip, UK BiLEVE Axiom30, and with the Affymetrix UK Biobank Axiom array31.
Imputation was performed by Wellcome Trust Centre for Human Genetics using
the Haplotype Reference Consortium (HRC) and the UK10K haplotype
resources32. This yielded a total of 96 million imputed variants, however only 40
million variants imputed using the HRC reference set were used in this study due
to quality issues with the remaining variants.
GWAS and meta-analysis. Logistic regression assuming an additive model was
used to test for association between variants and disease, treating disease status as
the response and expected genotype counts from imputation as covariates, and
using likelihood ratio test to compute two-sided P-values. The association analysis
for both the Icelandic and UKB datasets was done using software developed at
deCODE genetics27. For the Icelandic study group patients and controls are
matched on gender, age at inclusion, and information on county of origin within
Iceland are included as covariates to adjust for possible population stratiﬁcation.
For the UK datasets, cases and controls are restricted to individuals of genetically
conﬁrmed white British origin, and 40 principle components are included in the
analysis to adjust for population substructure. The total number, combined in the
Icelandic and UK GWASs, of variants tested in our analysis was 42.9 million (with
imputation info score > 0.80 in both study groups) in a total of 20,621 patients and
280,541 controls. All variants reported in Table 1 had imputation information
score > 0.95, except rs200383755, which had an imputation information score of
0.99 and 0.88 in the Icelandic and UK datasets, respectively. To account for
inﬂation in test statistics due to cryptic relatedness and stratiﬁcation, we applied the
method of LD score regression26 to estimate the inﬂation in the test statistics and
adjusted all P-values accordingly. The estimated correction factor for BPH/LUTS
based on LD score regression was 1.14 for the Icelandic and 1.03 for the UK
datasets. For the prostate cancer GWAS, the correction factor was 1.23 and 1.03,
respectively, for the Icelandic and the UK datasets.
Variants in the UK imputation dataset were mapped to NCBI Build38 positions
and matched to the variants in the Icelandic dataset based on allele variation. The
results from the two cohorts were combined using a ﬁxed-effect model in which the
cohorts were allowed to have different population frequencies for alleles and
genotypes but were assumed to have a common OR and weighted with the inverse
of the variance. Heterogeneity (Phet) was tested by comparing the null hypothesis of
the effect being the same in all populations to the alternative hypothesis of each
population having a different effect using a likelihood ratio test. I2 lies between 0
and 100% and describes the proportion of total variation in study estimates that is
due to heterogeneity.
Association signiﬁcance thresholds. The genome-wide signiﬁcance threshold for
the meta-analysis of GWASs of BPH/LUTS in the current study was corrected for all
42,907,111 being tested using a class-speciﬁc Bonferroni procedure based on func-
tional weights of classes of variants16 (i.e. P-value < ((0.05 × weight)/42,907,111). This
yielded signiﬁcance thresholds of: (i) 1.9 × 10−7 for 11,465 high-impact variants
(comprised of: stop-gained, frameshift, splice acceptor or donor); (ii) 3.9 × 10−8 for
197,583 moderate-impact variants (comprised of: missense, splice-region variants and
in-frame INDELs); (iii) 3.6 × 10−9 for 2,971,445 low-impact variants (comprised of:
synonymous variants 3′- and 5′-UTR variants); (iv) 1.8 × 10−9 for 5,015,711 inter-
genic and deep intronic variants overlapping DNase hypersensitivity sites; and (v)
5.9 × 10−10 for 34,710,908 other variants (intergenic and deep intronic).
Conditional analysis. We applied approximate conditional analyses (COJO),
implemented in the GCTA software17 to the meta-analysis summary statistics to
look for additional association signals at each of the genome-wide signiﬁcant loci.
LD between variants was estimated using a set of 8700 whole-genome-sequenced
Icelandic individuals. The analysis was restricted to variants within 1 Mb from the
index variants and that were present in both the Icelandic and UKB datasets. We
tested 14 loci and about 50,000 variants in the conditional analysis and report
variants with conditional P-value < 1.0 × 10−6, obtained using a logistic regression
model. The results from GCTA-COJO were veriﬁed by conditional analysis using
individual genotype data in the Icelandic and UK datasets separately and results
presented in Table 1 are obtained by meta-analyzing those results.
GWAS of serum levels of PSA. To study PSA levels among unaffected men in
Iceland, we excluded subjects who had been diagnosed with prostate cancer as
recorded by the ICR (between 1955 and 2016) or were known to have undergone
TURP between 1983 and 2017. PSA levels were quantile-standardized to a standard
normal distribution and corrected for age at measurement, county of birth, and time
to death using a generalized additive model with a smooth component on the age and
time to death. Most subjects had more than two PSA measurements. Hence, we used
the mean of the adjusted and standardized PSA values for each individual.
Quantitative traits were tested for association under the additive model using a
linear mixed model implemented in BOLT-LMM33. To account for inﬂation in test
statistics due to cryptic relatedness and stratiﬁcation, we applied the method of LD
score regression26. For each single-nucleotide polymorphism a classical linear
regression using the genotype as an additive covariate and the average PSA value as
a response was ﬁtted to test for association.
Genetic correlation and PRSs. We estimated the genetic correlation between pairs
of traits using the cross-trait LD score regression method26 and the summary
statistics from the Icelandic and UK datasets. In this analysis we used results for
about 1.2 million variants, well imputed in both datasets, and for LD information
we used pre-computed LD scores for European populations (downloaded from
https://data.broadinstitute.org/alkesgroup/LDSCORE/eur_w_ld_chr.tar.bz2). To
avoid bias due to overlapping samples, we calculated the genetic correlation
Table 2 Results from testing the association between polygenic risk scores based on UK data, and a phenotype status, based on
Icelandic data
PRSs Phenotype Effect (β) P-value PSA_increase/PRS_SD (%) 95% c.i. (%)
(a) Separately
PC PSA levels 0.089 9.8 × 10−68 16.3 (14.3, 18.3)
BPH/LUTS PSA levels 0.071 6.0 × 10−45 12.9 (10.9, 14.8)
(b) Jointly
PC PSA levels 0.074 4.1 × 10−43 13.3 (11.3, 15.3)
BPH/LUTS PSA levels 0.049 3.0 × 10−20 8.6 (6.7, 10.5)
Shown are results from testing the association of polygenic genetic risk scores (PRSs), based on effect estimates from the UK for: prostate cancer (PC) and benign prostatic hyperplasia/lower urinary
tract symptoms (BPH/LUTS), for correlation with serum levels of PSA (PSA levels) in 18,929 Icelandic males. Shown are the effect estimates (β), the two-sided P-values calculated using logistic
regression in R (v3.5), the percentage increase in PSA levels for each standard deviation (SD) increase in the PRSs, and the 95% conﬁdence intervals (c.i.)
In section a the results are shown separately for the PRSs of prostate cancer (PC) and BPH/LUTS, whereas in section b the results are shown jointly (i.e. after being conditioned for each other)
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06920-9
6 NATURE COMMUNICATIONS |          (2018) 9:4568 | DOI: 10.1038/s41467-018-06920-9 | www.nature.com/naturecommunications
between Icelandic GWAS summary statistic for one trait and the UK GWAS
summary statistic for the other traits, and the vice versa, and then meta-analyzed
those results.
We used PRS analyses of the GWAS results for one trait to investigate its
predictive power for another trait. The PRSs were calculated using genotypes for
about 630,000 well-imputed autosomal markers. For PRSs generated for Icelandic
individuals, we only used chip-typed individuals and we used effect estimated
based on GWAS analysis in the UK dataset. We estimated LD between markers
using 14,938 phased Icelandic samples and used this LD information to calculate
adjusted effect estimates using LDpred34. We created several PRSs assuming
different fractions of causal markers (the P parameter in LDpred), and selected the
PRSs that best predicted the trait itself. These PRSs were then used when we
calculate the correlation of the PRS with other traits. The number of individuals
belonging to each phenotype group is as follows: serum levels of PSA consisted of
18,929 Icelandic males; prostate cancer consisted of 3464 patients and 43,029
controls; and BPH/LUTS consisted of 5968 patients and 43,594 controls. The
correlation between the PRS and traits was calculated using logistic regression in R
(v3.5) (http://www.R-project.org) adjusting for year of birth and principle
components by including them as covariates in the analysis.
Bioinformatics analysis. For each lead variant, correlated variants (r2 > 0.8) were
identiﬁed using a set of 8700 whole-genome-sequenced Icelandic individuals. These
variants were then annotated by intersection with chromatin immunoprecipitation
(ChIP) signal data derived from the ENCODE project (www.encodeproject.org);
downloaded in pre-processed (MACS v2 algorithm) bigWig format representing
analysis of acetylation of lysine K27 of histone H3 (H3K27ac) in 118 different cell
types or primary tissues of which 8 were prostate-derived (epithelial cell of prostate,
prostate, RWPE1, RWPE2, PC-3, 22Rv1, C4-2B, and VCAP) (see Supplementary
Data 1 and 2). The signal P-values (derived from MACS v2) were adjusted by the
Benjamini-Hochberg procedure to account for multiple hypotheses and the sig-
niﬁcance threshold set at the 1% false discovery rate. The H3K27ac ChIP-seq data
for primary prostate epithelial cells, used in Fig. 2 and Supplementary Data 2, were
derived from accession number ENCFF704IWD. DNase hypersensitivity data for
the same sample (primary prostate epithelial cells), used in Supplementary Data 2,
were derived from accession number ENCFF5450IN. Super-enhancers deﬁned in
LNCaP prostate cancer cell line were derived from Hnisz et al.35 and the Hi-C data
for LNCaP used for deﬁning topologically associated domains are derived from
Encode (ENCSR346DCU), downloaded in pre-processed format through the 3D
Genome Browser (http://promoter.bx.psu.edu/hi-c/index.html).
A link between the lead variant (and all variants in the corresponding LD class;
r2 > 0.8) and neighboring gene(s) was established using GORpipe analysis tools36
and four bioinformatics data sources; Variant effect predictor37, JEME38, Fantom 5
promoters39, and the GTEx project40. Differently weighted scores to each data
source were given for each LD variant linked to a gene. The weighted scores for
each LD class were then summed for each lead variant. A conﬁdence of the link was
calculated as follows: (score highest gene− score second highest gene)/score
highest gene (see Supplementary Data 1). Transcription factors with signiﬁcantly
impacted binding also reported by Encode were identiﬁed using the matchPWM
function from Biostrings package in R to enable computational predictions for the
impact of single-nucleotide variants on DNA-binding protein occupancy.
Data availability
The Icelandic population WGS data have been deposited at the European Variant
Archive under accession code PRJEB8636. The authors declare that the data
supporting the ﬁndings of this study are available within the article, its Supple-
mentary Data ﬁles, and upon request. The UK Biobank data can be obtained upon
application (ukbiobank.ac.uk).
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